



NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES.

Press Release

STADA brings in Henshaw from Biogen to head Specialty as Kim leads Western Europe

- Ian Henshaw joined STADA on 1 July as EVP and Global Head Specialty
- Bryan Kim becomes Global Head Western Europe, STADA's largest region
- STADA CEO Peter Goldschmidt: "Ian's extensive successes in specialty, especially in fields of biosimilars and neurology, are a perfect fit with our fast-growing Specialty segment. With his clear growth ambitions, I am convinced that Bryan will drive commercialization capabilities and rigor across all three segments in Western Europe."

Bad Vilbel, Germany – 7 July 2025 – STADA has from July 1st welcomed former Biogen biosimilars head **Ian Henshaw** to the STADA Executive Committee (SEC) as Executive-Vice President (EVP) and Global Head of Specialty. This enables current Global Head of Specialty and member of STADA's Executive Committee, **Bryan Kim**, to assume responsibility for STADA's largest region, Western Europe, with immediate effect.

Henshaw is a successful executive who has more than 30 years of industry experience and a great network within the area. Most recently, he operated with full end-to-end responsibility as SVP and Global Head Biosimilars at Biogen, where he in total spent 10 years. Prior to that, Henshaw worked for more than six years at The Medicines Company, covering Emerging Markets, Neurocritical Care, and Business Development, having started his career at Eli Lilly.

Executive Board: Peter Goldschmidt (CEO) / Simone Berger / Miguel Pagan Fernandez / Boris Döbler
Chairman of the Supervisory Board: Dr. Günter von Au



Additionally, he served as Non-Executive Director at Samsung Bioepis, a biopharmaceutical company with a focus on biosimilars in different therapeutic areas.

"I am convinced that, with a leader of Ian's caliber, we will further accelerate our culture of agility and entrepreneurship to fulfill our vision of outperforming the market. His extensive successes in Specialty, especially in the fields of biosimilars and neurology, are a perfect fit with our fast-growing Specialty segment, enhancing our strategy for the long term," stated STADA CEO **Peter Goldschmidt**.

"Stepping into this role," Henshaw explained, "I feel incredibly fortunate to join STADA and a highly successful team that has already achieved so much under Bryan's leadership. I'm excited to drive execution excellence and work closely with the Specialty team to connect and collaborate with payors, providers, prescribers, patients, and partners."

Kim joined STADA in 2021 as Executive Vice President Global Specialty. Under his leadership, Specialty has been the fastest growing segment within STADA, through a scalable platform that has launched products in more than 30 countries globally with a portfolio that includes innovative medicines in neurology and nephrology, six marketed biosimilars, and specialty generics. Between 2021 and 2024, STADA's Specialty segment achieved a revenues compound annual growth rate (CAGR) of 15.9%.

"Under Bryan's leadership," Goldschmidt commented, "STADA has become a partner of choice in Specialty, with value-adding capabilities across the product lifecycle and a strong track record of approvals and launches. We believe Specialty will remain a key growth driver for the largest region within STADA, Western Europe, alongside our Consumer Healthcare and Generics segments. With his clear growth ambitions, I am convinced that Bryan will drive commercialization capabilities and rigor across all three segments, building on and accelerating our strategy of strong local entrepreneurs, while capitalizing on local company and brand heritage."

Executive Board: Peter Goldschmidt (CEO) / Simone Berger / Miguel Pagan Fernandez / Boris Döbler
Chairman of the Supervisory Board: Dr. Günter von Au



"I am thrilled to lead our crucial Western Europe business, along with some of the most proven general managers in the industry. We have great potential for further growth, and I am convinced that Western Europe will lead the way across all STADA business segments and outperform the competition," Kim stated.

Kim assumes responsibility for STADA's Western Europe region – which covers countries including France, the UK, Belgium, Ireland, Spain, Switzerland, Austria and the Netherlands – from **Stephan Eder**, who recently left the Group.

Disclaimer

Neither this communication nor the publication in which it is contained is for publication or distribution, directly or indirectly, in whole or in part, in or into the United States of America, including its territories and possessions, any state of the United States and the District of Columbia (the "United States"). This communication is not and does not constitute an offer to sell, or the solicitation of an offer to buy or subscribe for, securities to any person in the United States, Australia, Canada or Japan, or any other jurisdiction in which such offer may be restricted or unlawful.

Any securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or the securities laws of any state or other jurisdiction of the United States, and may not be offered, sold, subscribed, used, pledged, resold, allotted, delivered or otherwise transferred, directly or indirectly, in or into the United States absent such registration, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements under the Securities Act, and in compliance with any applicable securities laws of any state or other jurisdiction of the United States. There is no intention to register any securities referred to herein in the United States or to make a public offer of the securities in the United States.

About STADA Arzneimittel AG

STADA Arzneimittel AG is headquartered in Bad Vilbel, Germany. The company focuses on a three-pillar strategy consisting of consumer healthcare products, generics and specialty pharma. Worldwide, STADA Arzneimittel AG sells its products in over 100 countries. In financial year 2024, STADA achieved group revenues of € 4,059 million and adjusted constant-currency earnings before interest, taxes, depreciation and amortization (adj. cc EBITDA) of € 886 million. As of 31 December 2024, STADA employed 11,649 people worldwide.

Executive Board: Peter Goldschmidt (CEO) / Simone Berger / Miguel Pagan Fernandez / Boris Döbler
Chairman of the Supervisory Board: Dr. Günter von Au

**Additional information for journalists**

STADA Arzneimittel AG - Media Relations

Stadastrasse 2-18, 61118 Bad Vilbel - Germany

Phone: +49 (0) 6101 603-165

E-Mail: press@stada.de

Or visit us via our website at <https://www.stada.com/media/newsroom>

Follow [@stadaGroup](#) on LinkedIn

Additional information for capital market participants

STADA Arzneimittel AG - Investor & Creditor Relations

Stadastrasse 2-18, 61118 Bad Vilbel – Germany

Phone: +49 (0) 6101 603-4689

Fax: +49 (0) 6101 603-215

E-mail: ir@stada.de

Or visit us via our website at <https://www.stada.com/investor-relations/>

Executive Board: Peter Goldschmidt (CEO) / Simone Berger / Miguel Pagan Fernandez / Boris Döbler

Chairman of the Supervisory Board: Dr. Günter von Au